Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in Children and Adolescents With Generalized Myasthenia Gravis
NCT05265273Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2022
- Primary completion
- Jun 2027
- Countries
- 4
01
Overview
A Phase 3 trial of nipocalimab in myasthenia gravis (MG), sponsored by Janssen Pharmaceutical. Started Jul 2022; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05265273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265273.